Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure

Leuk Res. 2009 Jan;33(1):178-81. doi: 10.1016/j.leukres.2008.04.019. Epub 2008 Jun 2.

Authors

Daniele Focosi, Richard Eric Kast, Maria Rita Metelli, Edoardo Benedetti, Sara Galimberti, Federico Papineschi, Mario Petrini

PMID: 18513794
DOI: 10.1016/j.leukres.2008.04.019

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Cell Division*
Chemokine CXCL12 / antagonists & inhibitors*
Chemokine CXCL12 / metabolism
Dipeptidyl-Peptidase IV Inhibitors*
Female
Graft Rejection*
Hematopoietic Stem Cells / cytology
Hematopoietic Stem Cells / drug effects*
Humans
Hydrolysis
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / surgery*
Middle Aged
Protease Inhibitors / pharmacology*
Protease Inhibitors / therapeutic use
Pyrazines / pharmacology*
Pyrazines / therapeutic use
Sitagliptin Phosphate
Triazoles / pharmacology*
Triazoles / therapeutic use

Substances

Chemokine CXCL12
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Pyrazines
Triazoles
Sitagliptin Phosphate